Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment
Chengqi Yu,1 Leilei Jiang,2 Dan Yang,2 Xin Dong,2 Rong Yu,2 Huiming Yu2 1School of Basic Medical Science, Capital Medical University, Beijing, 100069, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Onc...
Main Authors: | Yu C, Jiang L, Yang D, Dong X, Yu R, Yu H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-10-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/anlotinib-hydrochloride-and-pd-1-blockade-as-a-salvage-second-line-tre-peer-reviewed-fulltext-article-OTT |
Similar Items
-
Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
by: Bai H, et al.
Published: (2024-02-01) -
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Dou XJ, et al.
Published: (2024-03-01) -
Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer
by: JIN Huimin, et al.
Published: (2022-10-01) -
Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
by: Li XY, et al.
Published: (2022-04-01) -
Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China
by: Chen XQ, et al.
Published: (2022-05-01)